CYTOMEDIX ANNOUNCES PARTICIPATION AT 2012 BIO INTERNATIONAL CONVENTION
GAITHERSBURG, Md. (June 19, 2012) – Cytomedix, Inc. (OTC/BB: CMXI) (the “Company”), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair, today announced that Martin P. Rosendale, Chief Executive Officer, will be a panel participant in a breakout session entitled, “Patient Centered Drug Development Strategy & Market Opportunity in Major Disease Categories,” taking place on Wednesday, June 20th from 10:00 – 11:30 a.m. ET at the 2012 BIO International Convention being held from June 18th – June 21st at the Boston Convention & Exhibition Center.
The session will include a panel of senior drug development, reimbursement/payer and clinical experts who will discuss the strategic opportunities for adjunctive and supportive therapies in blockbuster categories, and the increasing focus on patient-centered outcomes. Mr. Rosendale will discuss how Cytomedix’s autologous regenerative therapies respond to the market opportunities to be had for companies that locate the sweet spot where clinical needs intersect with policy priorities, specifically for therapies in blockbuster categories such as wound care, tissue repair and vascular disease.
About The 2012 BIO International Convention
The BIO International Convention brings together life science leaders and policy makers from around the globe. Over 15,000 leaders from more than 65 countries come to this global gathering, which covers the wide spectrum of life science innovations and application areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapies.
About Cytomedix, Inc.
Cytomedix, Inc. is an autologous regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds and the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell ("ALDHbr") technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit www.cytomedix.com.
Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix’ actual results may differ materially due to a number of factors, many of which are beyond Cytomedix’ ability to predict or control, including among many others, risks and uncertainties related to the Company’s ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company’s sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as “believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.
Cytomedix, Inc. Investor Inquiries
Martin Rosendale, Chief Executive Officer Anne Marie Fields
Andrew Maslan, Chief Financial Officer LHA
David Jorden, Executive Chairman email@example.com
(240) 499-2680 (212) 838-3777
# # #